Update under Regulation 30 read with Para A Part A of Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
MEDPLUS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Medplus Health Services has disclosed that its subsidiary, Optival Health Solutions Private Limited, received a suspension order from the Assistant Director, Drugs Control Administration, Hubli Circle, for a store at Kalyan Nagar, Dharwad, Karnataka. The Drug License of this single store has been suspended for three days, effective from the order dated 27 March 2026. The action was taken under Rule 65 of the Drugs and Cosmetics Act, 1940 and its Rules. The company estimates a potential revenue loss of around Rs 0.66 lakhs (approximately ₹66,000) from this three-day suspension. Medplus has reported the matter to BSE and NSE as required under SEBI Listing Regulations.
The financial impact is negligible — a three-day suspension of one store out of Medplus's large nationwide network results in only about Rs 0.66 lakhs in potential revenue loss. No material impact on the company's overall operations or financial position is expected, and the stock is unlikely to see any meaningful reaction.